SeaCrest Wealth Management LLC Acquires 163 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SeaCrest Wealth Management LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,688 shares of the medical equipment provider’s stock after acquiring an additional 163 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Zimmer Biomet were worth $802,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the company. Fairfield Bush & CO. purchased a new position in shares of Zimmer Biomet in the first quarter valued at $111,000. United Bank grew its position in shares of Zimmer Biomet by 4.1% in the first quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock valued at $1,416,000 after purchasing an additional 437 shares in the last quarter. Panagora Asset Management Inc. grew its position in shares of Zimmer Biomet by 153.9% in the first quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 5,942 shares in the last quarter. Aviva PLC grew its position in shares of Zimmer Biomet by 0.4% in the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock valued at $3,918,000 after purchasing an additional 137 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its position in shares of Zimmer Biomet by 11.2% in the first quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock valued at $5,348,000 after purchasing an additional 4,224 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ZBH shares. Raymond James lifted their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Barclays lifted their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. JPMorgan Chase & Co. lifted their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Finally, StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $137.84.

Zimmer Biomet Stock Down 0.5 %

Shares of Zimmer Biomet stock traded down $0.63 during midday trading on Friday, hitting $131.98. The company had a trading volume of 1,425,289 shares, compared to its average volume of 1,274,590. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The stock has a market capitalization of $27.07 billion, a P/E ratio of 26.99, a P/E/G ratio of 2.44 and a beta of 1.01. The company has a 50 day moving average of $125.46 and a 200 day moving average of $118.13. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.88 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.73%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.